Qvin’s Q-Pad Kit Receives the US FDA’s Approval as a Step to Revolutionize Women’s Health with Menstrual Sample Testing
Shots:
- The US FDA has approved Qvin’s Q-Pad and A1c Test, an at-home collection of menstrual samples to detect and monitor diabetic and pre-diabetic women. The kit measures the average blood sugar levels over a 3mos. period, by testing the A1c biomarkers in patients with diabetes
- The Q-Pad includes a removable strip that upon collection of the menstrual sample can be removed and sent to CLIA-Certified laboratories for clinical testing. The results are then received by the user through Qvin’s app
- Qvin jointly with researchers from academic institutions incl. Stanford University School of Medicine, has published peer-reviewed research identifying potential biomarkers that can be tracked through Q-Pad Kit incl. HPV screening for the prevention of cervical cancer
Ref: PR Newswire | Image: Qvin
Related News:- Pfizer and Myovant's Myfembree Receive the US FDA's Approval for Heavy Menstrual Bleeding Associated with Uterine Fibroids
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
